Global Cetuximab Market is segmented, by Geographical Region into United
States, China, Europe, and Japan. Cetuximab comes across as an epidermal growth
factor receptor (EGFR) inhibitor used to treat metastatic non-small cell lung
cancer, head and neck cancer, and metastatic colorectal cancer. Owing to the
collection of the EGFR-dependent intracellular signal pathways, the biological
effects of the blockade of ligand receptor binding by cetuximab are
wide-ranging. In preclinical in vitro and in vivo studies, it has been shown that
cetuximab acts as a constraint to tumor development and metastasis. EGFR is
articulated in many normal epithelial tissues including skin and hair follicles
in the Cetuximab Market.
Browse Cetuximab
Research Report at : https://www.millioninsights.com/industry-reports/cetuximab-market
Cetuximab is dispatched under the
trade name “Erbitux” in the U.S. and Canada by the drug company Bristol-Myers
Squibb and outside the U.S. and Canada by the drug company Merck KGaA. In
Japan, Merck Group, Bristol-Myers Squibb and Eli Lilly have a co-distribution.
In July 2009, the FDA did approve cetuximab (Erbitux) for treating colon cancer
with wild-type KRAS, since it had negligible effect in colorectal tumors
harboring a KRAS mutation (this also applied to the EGFR antibody panitumumab).
This was the first genetic test to guide treatment of cancer. In July 2012, the
FDA permitted a real-time PCR companion diagnostic test for KRAS, the Thera screen
KRAS test.
A diagnostic immunohistochemistry
assay (EGFR pharmDx) can be used to notice EGFR expression in the tumor
material. More than half of patients with metastatic colorectal cancer have an
EGFR-expressing tumor and are therefore eligible for treatment by cetuximab or
panitumumab, adhering to FDA guidelines. Cetuximab Market is segmented, by
Function into tumor growth and metastasis Proliferation, cell survival, cell
motility, cell invasion, tumor angiogenesis, and deoxyribonucleic acid (DNA) repair.
Request Sample Copy Market
Research: https://www.millioninsights.com/industry-reports/cetuximab-market/request-sample
Cetuximab Market is segmented, by
Uses into Metastatic Colorectal Cancer (cancer spread beyond the colon or
rectum), Squamous Cell cancer of head and neck, Non-small cell lung cancer,
Squamous cell skin cancer. Cetuximab
Market Key Players include Pfizer, Allergan, Alnylam Pharmaceuticals, Amgen,
Angstrom Pharmaceuticals, Acceleron Pharma, Biocon, Bionomics, CASI
Pharmaceuticals, Celgene Corporation, Enzon Pharmaceuticals, Five Prime
Therapeutics, Fujifilm Kyowa Kirin Biologics, Genentech, Genexine, Hetro Drugs,
Kyowas Hakko Kirin.
Get in touch
At Million Insights, we work with the aim to reach the
highest levels of customer satisfaction. Our representatives strive to
understand diverse client requirements and cater to the same with the most
innovative and functional solutions.
Contact Person:
Ryan Manuel,
Research Support Specialist, USA
Email: ryan@millioninsights.com
Million Insights
Office No. 302, 3rd Floor, Manikchand Galleria,
Model Colony, Shivaji Nagar, Pune, Maharashtra, 411016 India
Phone: 91-20-65300184
Email: sales@millioninsights.com
Visit Our Blog: www.millioninsights.blogspot.com
No comments:
Post a Comment